IRCT20200105046010N83招募中Unknown
Bioequivalence study of Empagliflozin 25 mg tablet manufactured by Kharazmi company versus originator brand in healthy volunteers in the fasted condition
kharazmi company0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •General Health (Liver, Heart, and Kidney)
- •Body Mass Index (18-28)
- •Informed consent
- •Age (18-55 years old)
排除标准
- •History of cardiovascular disease
- •History of liver and kidney disease
- •Alcohol and drug addiction
- •History of allergy to Empagliflozin
研究者
相似试验
招募中
不适用
Bioequivalence of EmpaglifloziDetermination of plasma concentration of Empagliflozin 25 mg pharmaceutical product.IRCT20210201050197N5Shahid Beheshti University of Medical Sciences24
招募中
Unknown
Bioequivalence study of Empaglifluzin 25mg tabletIRCT20200105046010N89Faran Pharmed company24
尚未招募
1 期
Bioequivalence study of empagliflozin 25 mg film-coated tablet in Thai healthy volunteersHealthy Thai VolunteersTCTR20230719003Macrophar Co., Ltd.28
尚未招募
1 期
Bioequivalence study of empagliflozin 25 mg film-coated tablet in Thai healthy volunteersThai healthy male and female subjects , Aged 18 to 55 years , BMI were within 18-30 kg/m2 , Good health confirming by physical and clinical.Empagliflozin, Bioequivalence studyTCTR20230711001Faculty of Medicine, Chulalongkorn University28
已完成
1 期
Bioequivalence of Empagliflozin 25 mg FCT in Healthy Thai volunteersBioequivalence study of 25 mg empagliflozin FCTTCTR20210324005nison Laboratories Co., Ltd.28